Apoptosis in severe, compensated pressure overload predominates in nonmyocytes and is related to the hypertrophy but not function

Ricardo J. Gelpi,¹,²*, Misun Park,¹ Shumin Gao,¹ Sunil Dhar,¹ Dorothy E. Vatner,¹ and Stephen F. Vatner¹

¹Cardiovascular Research Institute and the Department of Cell Biology & Molecular Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey; and ²Faculty of Medicine, Institute of Cardiovascular Physiopathology and the Department of Pathology, University of Buenos Aires, Buenos Aires, Argentina

Submitted 4 October 2010; accepted in final form 9 December 2010

Gelpi RJ, Park M, Gao S, Dhar S, Vatner DE, Vatner SF. Apoptosis in severe, compensated pressure overload predominates in nonmyocytes and is related to the hypertrophy but not function. Am J Physiol Heart Circ Physiol 300: H1062–H1068, 2011. First published December 10, 2010; doi:10.1152/ajpheart.00998.2010.—It is widely held that myocyte apoptosis in left ventricular hypertrophy (LVH) contributes to left ventricle (LV) dysfunction and heart failure. The main goal of this investigation was to determine if there is a statistical relationship among LV hypertrophy, apoptosis and LV function, and importantly whether the apoptosis occurs in myocytes or nonmyocytes in the heart. We used both rat and canine models of severe LVH induced by chronic thoracic aortic banding with resultant LV-aortic pressure gradients 145–155 mmHg and increases in LV/body weight of 58 and 70%. These models also provided the ability to examine transmural apoptosis in LVH. In both models, the overwhelming majority (88%) of apoptotic cells were nonmyocytes. The regressions for apoptosis vs. LVH were stronger for nonmyocytes than myocytes and also stronger in the subendocardium than the subepicardium. Importantly, LV systolic and diastolic wall stresses were normal, indicating that the apoptosis could not be attributed to LV stretch or heart failure. In addition, there was no relationship between the extent of apoptosis and LV ejection fraction, which actually increased (P < 0.05), in the face of elevated LV systolic pressure, indicating that greater apoptosis did not result in a decrease in LV function. Thus, in response to chronic, severe pressure overload, LVH in the absence of LV dilation, and elevated LV wall stress, apoptosis occurred predominately in nonmyocytes in the myocardial interstitium, more in the subendocardium than the subepicardium. The extent of apoptosis was linearly related to the amount of LV hypertrophy, but not to LV function.

METHODS

Experimental Animal Models

Aortic banding in rats and measurement of LV function. Male Sprague-Dawley rats (2.7 ± 0.1 mo of age) were used for transverse aortic constriction (TAC) and sham-operation in accordance with the Institutional Animal Care and Use Committee (IACUC) at the New Jersey Medical School. These studies were reviewed and approved by the IACUC at the New Jersey Medical School. Rats were anesthetized with a mixture of ketamine and xylazine (60 and 6 mg/kg, respectively). The sternum was cut to the level of the second rib and retracted sideward to expose the thymus and the aorta. TAC was created by tying a 6–0 braided polyester suture around the transverse aorta against a 21-gauge needle, which was then removed. Four weeks after aortic banding, closed-chest catheterization was performed. Two high-fidelity catheter tip transducers (1.4 Fr; Millar) were used; one was inserted in the right carotid artery and carefully advanced to the left ventricle (LV), and the other was placed in the left femoral artery and abdominal aorta. The pressures in the LV and abdominal aorta were measured simultaneously to calculate the pressure gradient.

* R. J. Gelpi and M. Park contributed equally to this work.

Address for reprint requests and other correspondence: S. F. Vatner, UMDNJ-New Jersey Medical School, Dept. of Cell Biology & Molecular Medicine, 185 South Orange Ave., MSB G-609, Newark, NJ 07103 (e-mail: vatnersf@umdnj.edu).
Transcardiac echocardiography was performed using an Acuson Sequoia 256 ultrasound system with a 13-MHz linear transducer. Echocardiography studies were performed under light anesthesia (Avertin, 2.5%-0.012 ml/g ip), the chest was shaved, and the animal was then placed on a warmed pad. Electrode needles were connected to each limb (Grass Technologies), and the electrocardiogram was simultaneously recorded. Mice were imaged in a shallow left lateral decubitus position. Two-dimensional parasternal short-axis imaging plane was used to obtain M-mode tracings at the level of the papillary muscles. LV internal dimensions and LV wall thickness were determined at systole and diastole. End-diastolic measurements were taken at the maximal LV diastolic dimension, and end systole was defined as the time of the most anterior systolic excursion of the posterior wall. Measurements were taken from three consecutive beats for each rat. Systolic function was evaluated from LV dimensions by the cubed method as percentage of LV ejection fraction (LVEF): LVEF (%) = (LVEDD\(^3\) − LVESD\(^3\))/LVEDD\(^3\) × 100, where LVEDD and LVESD are LV end-diastolic diameter and LV end-systolic diameter, LV systolic wall stress (LVWS) was calculated as: LVWS (g/cm\(^2\)) = (1.35 × LVSP × LVDD\(^2\))/[4 × (LVPWs × (1 + LVPWs/LVIDs))], where LVSP stands for LV systolic pressure and LVIDs and LVPWs stand for LV internal diameter and LV posterior wall thickness in systole, respectively. The same calculation was performed for LV diastolic wall stress but considering the diastolic pressure and dimensions.

**Aortic banding in dogs and LV function measurement.** Mongrel dogs of either sex at 8–10 wk of age were anesthetized with 12.5 mg/kg sodium thiamylal maintained with halothane anesthesia (1–2 vol/100 vol) and ventilated with a respirator (Harvard apparatus). A right thoracotomy was performed through the fourth intercostal space and the coronary arteries was isolated and dissected free of surrounding tissue. A 1-cm-wide Teflon cuff was placed around the aorta and tightened to each limb (Grass Technologies), and the electrocardiogram was simultaneously recorded. Mice were imaged in a shallow left lateral decubitus position. Two-dimensional parasternal short-axis imaging plane was used to obtain M-mode tracings at the level of the papillary muscles. LV internal dimensions and LV wall thickness were determined at systole and diastole. End-diastolic measurements were taken at the maximal LV diastolic dimension, and end systole was defined as the time of the most anterior systolic excursion of the posterior wall. Measurements were taken from three consecutive beats for each rat. Systolic function was evaluated from LV dimensions by the cubed method as percentage of LV ejection fraction (LVEF): LVEF (%) = (LVEDD\(^3\) − LVESD\(^3\))/LVEDD\(^3\) × 100, where LVEDD and LVESD are LV end-diastolic diameter and LV end-systolic diameter, LV systolic wall stress (LVWS) was calculated as: LVWS (g/cm\(^2\)) = (1.35 × LVSP × LVDD\(^2\))/[4 × (LVPWs × (1 + LVPWs/LVIDs))], where LVSP stands for LV systolic pressure and LVIDs and LVPWs stand for LV internal diameter and LV posterior wall thickness in systole, respectively. The same calculation was performed for LV diastolic wall stress but considering the diastolic pressure and dimensions.

Detection of Apoptosis

Tissue samples of LV from rat and dog were fixed by immersion in 10% neutralized buffered formalin and embedded in paraffin. After 5-μm-thick serial sectioning of heart paraffin block, DNA fragmentation was detected in situ by using the terminal deoxyribonucleotide transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) kit (Roche) according to the manufacturer’s instructions. Briefly, the paraffin sections were deparaffinized by immersing in xylene; rehydrated through 100, 95, 70, and 0% ethanol; after incubation with proteinase K (20 μg/ml) (Sigma-Aldrich), the sections were washed in PBS. DNA fragments in the sections were labeled with 2 nmol/l biotin-conjugated dUTP and 0.1 U/ml TdT for 30 min at 37°C. The incorporation of biotin-16-dUTP in DNA was determined by incubating the sections with streptavidin, Alexa Fluor-488 conjugated (1:500; Invitrogen). To discriminate apoptosis in nonmyocytes and myocytes, tissue sections were counterstained with rhodamine-conjugated wheat germ agglutinin (WGA) (DAPI; Vector Laboratories) described as in our previous study (13). WGA stains all cell membranes in LV myocytes. The pattern of WGA staining is seen not only at the outer membrane but also followed a striated pattern in myocytes (Fig. 2).

**Immunohistochemical Staining**

For characterization of cell types of apoptotic nonmyocytes, 5-μm serial tissue sections were immunostained with the following antibodies: mouse anti-rat CD68 (1:50 dilution; AbD Serotec) for macrophages; mouse monoclonal anti-heat shock protein (HSP) 47 (1:100 dilution; Stressgen) for fibroblasts; and isoelectin GS-IB4 from Griffonia simplicifolia, Alexa Fluor-568 conjugated (1:50 dilution; Invitrogen) for endothelial cells. Antigen retrieval was performed by immersing sections in 10 mM citrate buffer (pH 6.0) and boiling under pressure for 10–20 min. The tissue sections were incubated with the blocking solution (Protein Block Serum-Free, Dako) for 15 min at room temperature. Sections were incubated with primary antibody at 4°C for overnight, washed in PBS, and then incubated later with goat anti-mouse Alexa Fluor-555-conjugated (Invitrogen) secondary antibody. Apoptotic nonmyocytes were detected by dual staining with TUNEL assay.

**Statistics**

Data reported are means ± SE. Student’s t-tests were used to compare sham with 4 wk TAC with a significance level of P < 0.05. Simple regressions were conducted with LV/body weight as the dependent variable and apoptosis as the independent variable. Wherever subendocardium was being compared with subepicardium, the paired t-tests were applied to compare their means at the P < 0.05 significance level.

**RESULTS**

The extent of LVH and the hemodynamics are shown in Table 1 (rat) and Table 2 (dog). The LV/aortic pressure gradients were similar in rats (151 ± 7 mmHg) and dogs (143 ± 17 mmHg). The amount of LVH, i.e., the LV/body weight, in-
creased similarly in rats 58% and dogs 70%. LV wall stress was normalized by LVH, and LV end-diastolic pressure was not elevated in LVH. Lung/body weight, an index of heart failure, was not elevated with LVH in rats (Table 1). LV function did not decline in the dog model and actually increased ($P < 0.05$) in the rat model. For example, in rats, LV fractional shortening was elevated in LVH (40 $\pm$ 1.7%) compared with sham (35 $\pm$ 1.0%), and both positive and negative LV dP/dt were significantly increased (Table 1).

In Figs. 1–6, the amount of apoptosis was evaluated for total apoptotic cells (both myocytes and nonmyocytes combined) as well as for only myocytes and only nonmyocytes. In Figs. 1–6, the data are presented for both the subendocardium and the subepicardium. The amount of apoptosis tended to be greater, but not significantly, in the subendocardium compared with subepicardium for total cells and for nonmyocytes. Data were similar in dogs with LVH. The bar graphs in Fig. 1 show the apoptosis data from rats (Fig. 1A) and dogs (Fig. 1B). In the rat model, the percentage of apoptotic cells for nonmyocytes was five- to sevenfold greater (0.12 $\pm$ 0.01, $P < 0.05$) than for myocytes (0.02 $\pm$ 0.00), and this was observed both in the subendocardium and subepicardium. The detection of apoptosis was performed by double staining with TUNEL and WGA for discriminating apoptotic myocytes and nonmyocytes (Fig. 2A). The representative photographs of apoptotic myocytes and apoptotic nonmyocytes are shown in Fig. 2, B and C.

To characterize the cell types of TUNEL-positive nonmyocytes, the rat myocardial sections were stained with antibodies

Table 2. Dog physiological parameters

|                          | Sham ($n=4$) | TAC ($n=5$) |
|--------------------------|-------------|-------------|
| LV/BW                    | 4 $\pm$ 0.3 | 7 $\pm$ 0.6* |
| LV FS, %                 | 23 $\pm$ 2.3| 21 $\pm$ 3.8 |
| Heart rate, beats/min    | 87 $\pm$ 3.0| 91 $\pm$ 6.0 |
| LVEDP, mmHg              | 9 $\pm$ 1.2 | 12 $\pm$ 2.1 |
| LV +dP/dt, mmHg/s        | 3,179 $\pm$ 151 | 3,379 $\pm$ 121 |
| LV -dP/dt, mmHg/s        | 2,927 $\pm$ 190 | 3,978 $\pm$ 326 |
| LV systolic wall stress, g/cm$^2$ | 204 $\pm$ 17 | 249 $\pm$ 26 |
| LV diastolic wall stress, g/cm$^2$ | 22 $\pm$ 2.0 | 17 $\pm$ 1.0 |
| LV-aortic pressure gradients, mmHg | 143 $\pm$ 17 |           |

Values are means $\pm$ SE; $n$, no. of dogs. *$P < 0.05$.

Fig. 1. A: apoptosis in rat model of transverse aortic constriction (TAC). This figure compares the apoptosis (%) in left ventricular hypertrophy (LVH) after 4 wk of TAC (filled bars) vs. sham-operated rats (open bars) in the subendocardium (left) and subepicardium (right) for myocytes and for nonmyocytes. Apoptosis increased significantly more in LVH for both nonmyocytes and myocytes subendocardially (left) and for nonmyocytes subepicardially (right). B: dog model of TAC. The data resembled those from the rat model. Apoptosis is compared in 4 wk TAC with sham ($*P < 0.05$).
recognizing macrophages (CD68), endothelial cells (isolectin GS-IB4), and fibroblasts (HSP47). Representative images of apoptotic nonmyocytes in LVH are shown in Fig. 3.

The regression relationships between the amount of apoptosis and the amount of hypertrophy are shown for total cells (Fig. 4), nonmyocytes (Fig. 5), and myocytes (Fig. 6). The $R^2$ and $P$ values for the regressions are shown in Figs. 4–6. There were significant linear relationships between the amount of apoptosis and the amount of hypertrophy in the subendocardium for total cells and for nonmyocytes. However, the corresponding relationships were weaker in the subepicardium as reflected by the $R^2$ value and were not significant for myocytes, most likely because the amount of apoptosis in myocytes was relatively trivial. There was virtually no relationship between...
DISCUSSION

The major finding of the present investigation was that apoptosis in the severe but well-compensated hypertrophied heart occurs not in myocytes, as previously thought, but rather predominantly in interstitial nonmyocytes and that it is related to the extent of LVH. Nonmyocyte apoptosis has been noted before in models of heart failure, particularly those that involve injury to the heart, e.g., ischemia (8, 12, 15) or with pressure overload LVH where LV wall stress is increased or LV decompensation has occurred (3, 5, 13). However, almost all studies of apoptosis and LVH have concluded that the apoptosis affected myocytes (1, 2, 4, 10, 12, 13, 16). Furthermore, most of these studies did not document that the LVH was...
compensated and wall stress was normalized. This is an important point since apoptosis is known to be increased with myocardial dilatation and in heart failure (1, 5, 9, 14, 15). In the current investigation, both in the rat and the dog model of chronic pressure overload induced by thoracic aortic banding, the pressure gradients from LV to aorta were higher (145–155 mmHg) than most other previous studies, but the hearts were well compensated, i.e., LV end-diastolic pressure was not elevated and LV systolic and diastolic wall stresses were normal. Surprisingly, LV function was enhanced, as reflected by significantly increased LV fractional shortening in the face of markedly elevated LV systolic pressure along with increased LV dP/dt.

LVH and cardiac remodeling contribute to the development and progression of heart failure. However, the mechanisms that contribute to the structural changes that underlie progressive cardiac remodeling are only partially understood. Although it is generally held that LVH results in enhanced apoptosis of myocytes and that the loss of these myocytes is an important mechanism leading to decompensation of the hypertrophied heart, resulting in heart failure (1, 2, 4, 10, 12, 16), our data do not support this concept for two reasons. First, the amount of myocyte apoptosis was relatively trivial such that there would be an insignificant amount of loss of myocardial mass. Second, there was no relationship between the amount of apoptosis and LV function, i.e., LV ejection fraction. If increased apoptosis was the cause of reduced LV function, then there should have been at least a trend toward reduced function in those hearts that showed the most apoptosis. However, this was not observed, indicating, as a minimum, that the amount of apoptosis that occurred in this study with severe LVH was not sufficient to affect cardiac function adversely. Because the overwhelming majority of apoptotic cells were in nonmyocytes, it is not surprising that LV function was not compromised by the apoptosis. These data are also consistent with the results from a prior study from our laboratory in a monkey model of myocardial infarction and heart failure (14). Although the amount of apoptosis increased when heart failure developed in that study (14), the apoptosis still occurred predominantly in nonmyocytes.

An elegant study by Wencker et al. (17), using a transgenic model to induce myocyte apoptosis, found that amounts of myocyte apoptosis similar to what was observed in the current study led to LV dysfunction, heart failure, and dilation (17). If the amount of apoptosis is similar in the two studies, it raises the questions why did LV function decrease in the transgenic model? Or conversely, why did LV function improve in the current model of chronic pressure overload used in the current investigation? The differences in the two studies are not easily reconciled. One difference is the use of a physiological intervention, chronic pressure overload in an otherwise normal animal vs. a transgenic model that may affect other genes and signaling pathways. In support of the possibility that the transgenic model is affected by more than apoptosis, it would be important to know if LV weight was significantly less in the transgenic model due to a loss of myocytes before heart failure developed, since the underlying concept is that myocyte apoptosis leads to reduced contractile elements in the heart thereby compromising LV contraction; however, these data are not available (17). Conversely, if the LV mass does not decrease
due to the excessive myocyte apoptosis, then how does the heart fail? Second, in our study, we demonstrated the importance of nonmyocyte apoptosis, which conceivably could be salutary and offset the adverse effects of myocyte apoptosis. One other consideration that needs to be examined in both models is whether apoptosis is a physiological, not a pathological, process whereby damaged myocytes are replaced by myocyte regeneration, which could offset the effects of apoptosis. Taking all these considerations together, we believe our study challenges the concept that myocyte apoptosis is a major mechanism leading to heart failure in the setting of chronic pressure overload LVH. Certainly, in the confines of the current protocol, there was no evidence that myocyte apoptosis, which increased linearly with LVH, had any adverse effect on LV function. However, more studies will have to be done in the future to determine the extent to which myocyte apoptosis is detrimental or the nonmyocyte apoptosis is salutary, particularly extending the model to LV decompensation.

There were two other findings of the present study that have not been appreciated previously. The first is that there was a significant relationship between the amount of apoptosis and the amount of hypertrophy. Although this might be predicted from prior studies demonstrating increased apoptosis with LVH, it has not been shown clearly previously. The second new finding is that we examined apoptosis in the subendocardium and the subepicardium. It might be predicted that the apoptosis would be more severe subendocardially, since that part of the hypertrophied heart is more susceptible to ischemia. We found that the relationships between the amount of apoptosis and the amount of LVH were stronger in the subendocardium for both myocytes and nonmyocytes, but the amount of apoptosis was not significantly greater in the subendocardium. A previous study found that there was more apoptosis subendocardially, when the hypertrophied heart began to fail, but not in well-compensated LVH (4).

In summary, these data indicate that myocyte apoptosis is relatively minor in response to pressure overload LVH in the absence of LV dilation and elevated LV wall stress, but rather the increased apoptosis predominantly occurs in nonmyocytes in the myocardial interstitium, which is linearly related to the amount of LVH. In contrast, there was no significant relationship between the amounts of apoptosis of LV systolic function, which actually increased in the rat model of severe hypertrophy. These results suggest that mechanisms other than apoptosis may be more important in mediating the transition to heart failure in the hypertrophied heart.

GRANTS
This study was supported, in part, by NIH Grants HL-069020, HJ-101420, HL-033107, HL-093481, HL-102472, HL-069752, AG-027211, and HL-095888.

DISCLOSURES
No conflicts of interest are declared by the authors.

REFERENCES
1. Anselmi A, Gaudino M, Baldi A, Vetrovec GW, Bussani R, Possati G, Abbate A. Role of apoptosis in pressure-overload cardiomyopathy. J Cardiovasc Med (Hagerstown) 9: 227–232, 2008.
2. Choi YH, Cowan DB, Moran AM, Colan SD, Stamm C, Takeuchi K, Friechs I, del Nido PJ, McGowan FX Jr. Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium. J Thorac Cardiovasc Surg 137: 1356–1362, 2009.
3. Condorelli G, Morisco C, Stassi G, Notte A, Farina F, Sgaramella G, de Rienzo A, Roncarati R, Trimarco B, Lembo G. Increased cardio-myocyte apoptosis and changes in proapoptotic and antiapoptotic genes and bcl-2 during left ventricular adaptational changes to chronic pressure overload in the rat. Circulation 99: 3071–3078, 1999.
4. Engel D, Peshock R, Armstrong RC, Sivasubramanian N, Mann DL. Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. Am J Physiol Heart Circ Physiol 287: H1303–H1311, 2004.
5. Ikeda S, Hamada M, Hiwada K. Contribution of non-cardiomyocyte apoptosis to cardiac remodeling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive rats. Clin Sci (Lond) 97: 239–246, 1999.
6. Jiang L, Huang Y, Hunyor S, dos Remedios CG. Cardiomyocyte apoptosis is associated with increased wall stress in chronic failing left ventricle. Eur Heart J 24: 742–751, 2003.
7. Jhugdutt BI. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108: 1395–1403, 2003.
8. Kanamori H, Takekura G, Li Y, Okada H, Maruyama A, Aoyama T, Miyata S, Esaki M, Ogino A, Nakagawa M, Ushikoshi H, Kawasaki M, Minatoguchi S, Fujiwara H. Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan. Am J Physiol Heart Circ Physiol 292: H2184–H2194, 2007.
9. Leri A, Barlucchi L, Limana F, Depta A, Darzyznkiewicz Z, Hintze TH, Kajstura J, Nadal-Ginard B, Anversa P. Telomerase expression and activity are coupled with myocyte proliferation and preservation of telomeric length in the failing heart. Proc Natl Acad Sci USA 98: 8626–8631, 2001.
10. Liu XM, Ma YT, Yang YN, Liu F, Chen BD, Han W, Zhang JF, Gao XM. Downregulation of survival signaling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure. Clin Exp Pharmacol Physiol 36: 1054–1061, 2009.
11. Li Y, Takekura G, Okada H, Miyata S, Kanamori H, Maruyama R, Esaki M, Li L, Ogino A, Ohno T, Kondo T, Nakagawa M, Minatoguchi S, Fujiwara T, Fujiwara H. ANG II type 1A receptor signaling causes unfavorable scar dynamics in the postinfarct heart. Am J Physiol Heart Circ Physiol 292: H946–H953, 2007.
12. Moorjani N, Ahmad M, Catarino P, Brittin R, Trabzuni D, Al-Shahi R, Park M, Shen YT, Gaussin V, Heyndrickx GR, Bartunek J, Resuello M, Muller P, Kazakov A, Semenov A, Bohm M, Laufs U. Contribution of non-cardiomyocyte apoptosis to cardiac remodeling that occurs in the transition from compensated hypertrophy to heart failure. J Am Coll Cardiol 48: 1451–1458, 2006.
13. Muller P, Kazakov A, Semenov A, Bohm M, Laufs U. Pressure-induced cardiac overload induces upregulation of endothelial and myocardial progenitor cells. Cardiovasc Res 77: 151–159, 2008.
14. Park M, Shen YT, Gaal-Gyimesi AM, Heyndrickx GR, Bartunek J, Resuello RR, Natividad FF, Kitis RN, Vatner DE, Vatner SF. Apoptosis predominates in nonmyocytes in heart failure. Am J Physiol Heart Circ Physiol 297: H785–H791, 2009.
15. Rufolo RR Jr, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 32, Suppl 1: S22–S30, 1998.
16. Sharma AK, Dhingra S, Chaperon S, Singh PK. Activation of apoptotic processes during transition from hypertrophy to heart failure in guinea pigs. Am J Physiol Heart Circ Physiol 293: H1384–H1390, 2007.
17. Wencker D, Chandra M, Yuan K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC, Kitis RN. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 111: 1497–1504, 2003.
18. Zhao J, Li J, Li W, Li Y, Shan H, Gong Y, Yang B. Effects of spironolactone on atrial structural remodeling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 159: 1584–1594, 2010.